肺疾患治療薬の世界市場レポート 2025年

肺疾患治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には719億1,000万米ドルに成長し、CAGRは5.7%となります。予測期間中の成長は、ヘルスケアインフラの拡大、心血管疾患の有病率の上昇、在宅ケア治療の成長、肺疾患に対する意識の高まり、喘息の有病率の上昇などに起因すると考えられます。この期間に予想される主な動向には、技術の進歩、AI主導の創薬、スマート吸入器の採用、ナノテクノロジーに基づく製剤、遺伝子治療の発展などがあります。

呼吸器疾患の有病率の増加は、肺疾患治療薬市場の拡大を促進すると予想されます。呼吸器疾患は、肺や気道に影響を及ぼし、正常な呼吸や酸素交換を妨げる病状です。呼吸器疾患の発生率は、肺の損傷や慢性疾患の原因となる喫煙などの要因によって上昇しています。肺疾患治療薬は、肺機能を改善し、炎症を抑え、気道閉塞を緩和して呼吸を促進することで、これらの症状を管理するのに不可欠です。例えば、2023年11月、米国を拠点とする政府機関である労働統計局は、2022年の民間産業雇用者の疾病率は、フルタイム換算（FTE）労働者1万人当たり45.2件となり、2021年の37.7件から上昇したと報告しました。この増加は主に呼吸器疾患の発生率の上昇によるもので、2021年には1万FTE労働者当たり27.8件であったものが、2022年には35.8件に増加しました。その結果、呼吸器疾患の有病率の上昇が肺疾患治療薬市場の成長を促進しています。

肺疾患治療薬市場の主要企業は、シングル吸入器3剤併用療法（SITT）などの革新的な治療法の開発に注力し、治療効果の向上、患者のアドヒアランスの強化、より良い疾患管理のための投薬レジメンの簡素化を図っています。単回吸入3剤併用療法は、慢性閉塞性肺疾患（COPD）などの慢性呼吸器疾患をより効果的に管理するために、3つの異なる薬剤を1つの吸入器にまとめるものです。例えば、2022年4月、インドの製薬会社グラクソ・スミスクライン・ファーマシューティカルズ・リミテッドは、インド初のCOPD患者向け単回吸入式3剤併用療法であるトレレジー・エリプタを発売しました。この治療薬は、フルチカゾンフロエート、ウメクリジニウム、ビランテロールを配合し、肺機能を改善し、症状の再燃を抑えます。革新的なEllipta吸入器は、正確な用量を確保し、複数の吸入器による治療と比較して患者のアドヒアランスを向上させます。インドには1億人を超えるCOPD患者がおり、今回の発売は治療を簡素化し、患者の転帰を改善することを目的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界肺疾患治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の肺疾患治療薬市場：成長率分析
• 世界の肺疾患治療薬市場の実績：規模と成長, 2019-2024
• 世界の肺疾患治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界肺疾患治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の肺疾患治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 吸入コルチコステロイド
• 長時間作用型β2刺激薬
• 抗ヒスタミン薬
• 血管拡張薬
• 短時間作用型β2刺激薬
• その他の薬物クラス
• 世界の肺疾患治療薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 喘息
• 慢性閉塞性肺疾患（COPD）
• アレルギー性鼻炎
• 肺動脈高血圧
• 嚢胞性線維症
• その他の適応症
• 世界の肺疾患治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小売薬局
• オンライン薬局
• 病院薬局
• 世界の肺疾患治療薬市場吸入コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベクロメタゾン
• ブデソニド
• フルチカゾン
• モメタゾン
• シクレソニド
• 世界の肺疾患治療薬市場長時間作用型β2刺激薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• サルメテロール
• フォルモテロール
• インダカテロール
• オロダテロール
• ビランテロール
• 世界の肺疾患治療薬市場抗ヒスタミン薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• セチリジン
• ロラタジン
• フェキソフェナジン
• ジフェンヒドラミン
• レボセチリジン
• 世界の肺疾患治療薬市場血管拡張薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エンドセリン受容体拮抗薬
• ホスホジエステラーゼ5阻害剤
• プロスタサイクリン類似体
• 世界の肺疾患治療薬市場短時間作用型β2刺激薬（SABA）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルブテロール
• レバルブテロール
• テルブタリン
• フェノテロール
• ピルブテロール
• 世界の肺疾患治療薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 酵素
• 抗生物質
• 抗ロイコトリエン

第7章 地域別・国別分析

• 世界の肺疾患治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の肺疾患治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肺疾患治療薬市場：競合情勢
• 肺疾患治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck Sharp & Dohme Limited Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline plc
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Grifols S.A.
• Chiesi Farmaceutici S.p.A.
• Cipla Limited
• Lupin Pharmaceuticals Inc.
• United Therapeutics Corporation
• Mallinckrodt Pharmaceuticals plc
• Glenmark Pharmaceuticals Limited
• Circassia Pharmaceuticals plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 肺疾患治療薬市場2029：新たな機会を提供する国
• 肺疾患治療薬市場2029：新たな機会を提供するセグメント
• 肺疾患治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pulmonary drugs are medications designed to target the respiratory system to enhance lung function, reduce inflammation, and manage airway disorders. They are commonly used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other respiratory illnesses.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main classes of pulmonary drugs include inhaled corticosteroids, long-acting beta-2 agonists, antihistamines, vasodilators, short-acting beta-2 agonists, and others. Inhaled corticosteroids are anti-inflammatory medications delivered directly to the lungs via inhalers, helping to manage chronic respiratory conditions such as asthma and COPD by reducing airway inflammation and preventing flare-ups. These drugs are used for indications such as asthma, COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and more. They are distributed through various channels, including retail pharmacies, online pharmacies, and hospital pharmacies.

The pulmonary drugs market research report is one of a series of new reports from The Business Research Company that provides pulmonary drugs market statistics, including the pulmonary drugs industry global market size, regional shares, competitors with the pulmonary drugs market share, detailed pulmonary drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the pulmonary drugs industry. This pulmonary drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pulmonary drugs market size has grown strongly in recent years. It will grow from$54.28 billion in 2024 to $57.53 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth during the historic period can be attributed to the rise in the prevalence of respiratory diseases, an increase in smoking rates, the growing geriatric population, expanded healthcare access, and the surge in pollution levels.

The pulmonary drugs market size is expected to see strong growth in the next few years. It will grow to$71.91 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth during the forecast period can be attributed to the expansion of healthcare infrastructure, the rising prevalence of cardiovascular diseases, the growth of homecare treatments, increased awareness about pulmonary diseases, and the rising prevalence of asthma. Key trends expected during this period include technological advancements, AI-driven drug discovery, the adoption of smart inhalers, nanotechnology-based formulations, and developments in gene therapy.

The growing prevalence of respiratory diseases is expected to drive the expansion of the pulmonary drugs market. Respiratory disorders are medical conditions that affect the lungs and airways, hindering normal breathing and oxygen exchange. The incidence of respiratory disorders is rising due to factors such as smoking, which contributes to lung damage and chronic diseases. Pulmonary drugs are vital in managing these conditions by improving lung function, reducing inflammation, and alleviating airway obstruction, thus enhancing breathing. For example, in November 2023, the Bureau of Labor Statistics, a U.S.-based government agency, reported that the illness rate among private industry employers in 2022 rose to 45.2 cases per 10,000 full-time equivalent (FTE) workers, up from 37.7 cases in 2021. This increase was primarily due to a higher incidence of respiratory illnesses, which grew from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. As a result, the rising prevalence of respiratory diseases is fueling the growth of the pulmonary drugs market.

Leading companies in the pulmonary drugs market are focusing on developing innovative treatments, such as single-inhaler triple therapy (SITT), to improve treatment effectiveness, enhance patient adherence, and simplify medication regimens for better disease management. Single-inhaler triple therapy combines three different medications into one inhaler to more effectively manage chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD). For example, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, an India-based pharmaceutical company, introduced Trelegy Ellipta, India's first single-inhaler triple therapy for COPD patients. This therapy combines fluticasone furoate, umeclidinium, and vilanterol to improve lung function and reduce symptom flare-ups. The innovative Ellipta inhaler ensures accurate dosing and enhances patient adherence compared to multiple-inhaler therapies. With over 100 million COPD patients in India, this launch aims to simplify treatment and improve patient outcomes.

In September 2024, Roivant Sciences Ltd., a U.S.-based biotechnology company, acquired a pulmonary hypertension drug from Bayer AG for an undisclosed sum. This acquisition enables Roivant to expand its respiratory portfolio and advance innovative treatments for pulmonary hypertension, thus improving patient outcomes and addressing unmet medical needs. Bayer AG, a Germany-based company, manufactures pulmonary drugs, including treatments for respiratory conditions such as pulmonary hypertension.

Major players in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, and Circassia Pharmaceuticals plc.

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pulmonary drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pulmonary drugs market consists of the sales of inhalers, nebulizers, bronchodilators, anti-inflammatory agents, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pulmonary Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pulmonary drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pulmonary drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pulmonary drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Inhaled Corticosteroids; Long Acting Beta-2 Agonists; Antihistamines; Vasodilators; Short Acting Beta-2 Agonists; Other Drug Classes
• 2) By Indication: Asthma; Chronic Obstructive Pulmonary Disease (COPD); Allergic Rhinitis; Pulmonary Arterial Hypertension; Cystic Fibrosis; Other Indications
• 3) By Distribution Channel: Retail Pharmacies; Online Pharmacies; Hospitals Pharmacies
• Subsegments:
• 1) By Inhaled Corticosteroids: Beclomethasone; Budesonide; Fluticasone; Mometasone; Ciclesonide
• 2) By Long-Acting Beta-2 Agonists: Salmeterol; Formoterol; Indacaterol; Olodaterol; Vilanterol
• 3) By Antihistamines: Cetirizine; Loratadine; Fexofenadine; Diphenhydramine; Levocetirizine
• 4) By Vasodilators: Endothelin Receptor Antagonists; Phosphodiesterase-5 Inhibitors; Prostacyclin Analogues
• 5) By Short-Acting Beta-2 Agonists (SABA): Albuterol; Levalbuterol; Terbutaline; Fenoterol; Pirbuterol
• 6) By Other Drug Classes: Monoclonal Antibodies; Enzymes; Antibiotics; Antileukotrienes
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck Sharp & Dohme Limited; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pulmonary Drugs Market Characteristics

3. Pulmonary Drugs Market Trends And Strategies

4. Pulmonary Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pulmonary Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pulmonary Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pulmonary Drugs Market Growth Rate Analysis
• 5.4. Global Pulmonary Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pulmonary Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pulmonary Drugs Total Addressable Market (TAM)

6. Pulmonary Drugs Market Segmentation

• 6.1. Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhaled Corticosteroids
• Long Acting Beta-2 Agonists
• Antihistamines
• Vasodilators
• Short Acting Beta-2 Agonists
• Other Drug Classes
• 6.2. Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Allergic Rhinitis
• Pulmonary Arterial Hypertension
• Cystic Fibrosis
• Other Indications
• 6.3. Global Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Online Pharmacies
• Hospitals Pharmacies
• 6.4. Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beclomethasone
• Budesonide
• Fluticasone
• Mometasone
• Ciclesonide
• 6.5. Global Pulmonary Drugs Market, Sub-Segmentation Of Long Acting Beta-2 Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Salmeterol
• Formoterol
• Indacaterol
• Olodaterol
• Vilanterol
• 6.6. Global Pulmonary Drugs Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cetirizine
• Loratadine
• Fexofenadine
• Diphenhydramine
• Levocetirizine
• 6.7. Global Pulmonary Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endothelin Receptor Antagonists
• Phosphodiesterase-5 Inhibitors
• Prostacyclin Analogues
• 6.8. Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists (SABA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Albuterol
• Levalbuterol
• Terbutaline
• Fenoterol
• Pirbuterol
• 6.9. Global Pulmonary Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Enzymes
• Antibiotics
• Antileukotrienes

7. Pulmonary Drugs Market Regional And Country Analysis

• 7.1. Global Pulmonary Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pulmonary Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pulmonary Drugs Market

• 8.1. Asia-Pacific Pulmonary Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pulmonary Drugs Market

• 9.1. China Pulmonary Drugs Market Overview
• 9.2. China Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pulmonary Drugs Market

• 10.1. India Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pulmonary Drugs Market

• 11.1. Japan Pulmonary Drugs Market Overview
• 11.2. Japan Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pulmonary Drugs Market

• 12.1. Australia Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pulmonary Drugs Market

• 13.1. Indonesia Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pulmonary Drugs Market

• 14.1. South Korea Pulmonary Drugs Market Overview
• 14.2. South Korea Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pulmonary Drugs Market

• 15.1. Western Europe Pulmonary Drugs Market Overview
• 15.2. Western Europe Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pulmonary Drugs Market

• 16.1. UK Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pulmonary Drugs Market

• 17.1. Germany Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pulmonary Drugs Market

• 18.1. France Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pulmonary Drugs Market

• 19.1. Italy Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pulmonary Drugs Market

• 20.1. Spain Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pulmonary Drugs Market

• 21.1. Eastern Europe Pulmonary Drugs Market Overview
• 21.2. Eastern Europe Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pulmonary Drugs Market

• 22.1. Russia Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pulmonary Drugs Market

• 23.1. North America Pulmonary Drugs Market Overview
• 23.2. North America Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pulmonary Drugs Market

• 24.1. USA Pulmonary Drugs Market Overview
• 24.2. USA Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pulmonary Drugs Market

• 25.1. Canada Pulmonary Drugs Market Overview
• 25.2. Canada Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pulmonary Drugs Market

• 26.1. South America Pulmonary Drugs Market Overview
• 26.2. South America Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pulmonary Drugs Market

• 27.1. Brazil Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pulmonary Drugs Market

• 28.1. Middle East Pulmonary Drugs Market Overview
• 28.2. Middle East Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pulmonary Drugs Market

• 29.1. Africa Pulmonary Drugs Market Overview
• 29.2. Africa Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pulmonary Drugs Market Competitive Landscape And Company Profiles

• 30.1. Pulmonary Drugs Market Competitive Landscape
• 30.2. Pulmonary Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck Sharp & Dohme Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Pulmonary Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca plc
• 31.3. Novartis AG
• 31.4. GlaxoSmithKline plc
• 31.5. Mylan N.V.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Grifols S.A.
• 31.9. Chiesi Farmaceutici S.p.A.
• 31.10. Cipla Limited
• 31.11. Lupin Pharmaceuticals Inc.
• 31.12. United Therapeutics Corporation
• 31.13. Mallinckrodt Pharmaceuticals plc
• 31.14. Glenmark Pharmaceuticals Limited
• 31.15. Circassia Pharmaceuticals plc

32. Global Pulmonary Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pulmonary Drugs Market

34. Recent Developments In The Pulmonary Drugs Market

35. Pulmonary Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Pulmonary Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pulmonary Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pulmonary Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34941_Pulmonary_Drugs_GMR_2025